title: First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
authors.affiliation: a Division of Thoracic Oncology , European Institute of Oncology , Milan , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Passaro
authors.affiliation: a Division of Thoracic Oncology , European Institute of Oncology , Milan , Italy.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Spitaleri
authors.affiliation: a Division of Thoracic Oncology , European Institute of Oncology , Milan , Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: de Marinis
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR; NSCLC; TKI; angiogenesis; bevacizumab; erlotinib; tyrosine kinase inhibitor